NCT02971397View on ClinicalTrials.gov

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

August 8, 2018

Conditions
Acute Myeloid Leukemia
Interventions
PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Cytarabine

Given IV

DRUG

Daunorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02971397 - Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter